These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11138460)

  • 1. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines.
    Pace E; Melis M; Siena L; Bucchieri F; Vignola AM; Profita M; Gjomarkaj M; Bonsignore G
    Cancer Chemother Pharmacol; 2000; 46(6):467-76. PubMed ID: 11138460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
    Siena L; Pace E; Ferraro M; Di Sano C; Melis M; Profita M; Spatafora M; Gjomarkaj M
    Immunology; 2014 Feb; 141(2):242-55. PubMed ID: 24128051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
    Siena L; Cipollina C; Di Vincenzo S; Ferraro M; Bruno A; Gjomarkaj M; Pace E
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):705-716. PubMed ID: 29435611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression.
    Kurdow R; Schniewind B; Zoefelt S; Boenicke L; Boehle AS; Dohrmann P; Kalthoff H
    Langenbecks Arch Surg; 2005 Jun; 390(3):243-8. PubMed ID: 15726400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
    Rundall BK; Denlinger CE; Jones DR
    Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.
    Jones DR; Broad RM; Madrid LV; Baldwin AS; Mayo MW
    Ann Thorac Surg; 2000 Sep; 70(3):930-6; discussion 936-7. PubMed ID: 11016336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
    Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460.
    Ferreira CG; Span SW; Peters GJ; Kruyt FA; Giaccone G
    Cancer Res; 2000 Dec; 60(24):7133-41. PubMed ID: 11156422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
    Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells.
    Ikeda R; Vermeulen LC; Lau E; Jiang Z; Sachidanandam K; Yamada K; Kolesar JM
    Int J Oncol; 2011 Feb; 38(2):513-9. PubMed ID: 21152861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
    Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
    Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy.
    Lang DS; Droemann D; Schultz H; Branscheid D; Martin C; Ressmeyer AR; Zabel P; Vollmer E; Goldmann T
    Respir Res; 2007 Jun; 8(1):43. PubMed ID: 17567922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
    Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R
    Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
    Chougule MB; Patel A; Sachdeva P; Jackson T; Singh M
    PLoS One; 2011; 6(11):e27394. PubMed ID: 22102891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
    Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
    Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
    Loprevite M; Favoni RE; de Cupis A; Pirani P; Merlo F; Grossi F; Ardizzoni A
    Int J Oncol; 1999 Oct; 15(4):787-92. PubMed ID: 10493963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
    Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
    Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.